US FDA grants full approval for TIVDAK (tisotumab vedotin-tftv) by Pfizer and Genmab to treat recurrent/metastatic cervical cancer after chemotherapy failure.
Pfizer and Genmab announced that the US FDA has granted full approval for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This marks the first antibody-drug conjugate with proven overall survival data to receive full approval for this patient group. The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial.
April 29, 2024
20 Articles